Biofrontera Inc. Adopts Limited Duration Shareholder Rights Plan
WOBURN, Mass., Oct. 14, 2022 (GLOBE NEWSWIRE) — Biofrontera Inc. (Nasdaq:BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that its Board of Directors has adopted a limited duration shareholder rights plan (the “Rights Plan”), and declared a dividend distribution of one preferred stock purchase right on each outstanding share of common stock, in order to protect the interest of all of the Company’s shareholders. The rights will be issued to shareholders of record on October 24, 2022 and will expire on October 13, 2023.
Related news for (BFRI)
- Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris
- 24/7 Market News Snapshot 25 August, 2025 – Biofrontera Inc. Common Stock (NASDAQ:BFRI)
- BIOFRONTERA INC. IS NEGOTIATING FUNDAMENTAL CHANGES TO ITS COOPERATION WITH BIOFRONTERA AG
- Biofrontera Inc. Announces Patent for Propylene Glycol-Free Formula of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Now Listed in FDA Orange Book
- Biofrontera Inc. Reports First Quarter 2025 Financial Results and Provides a Business Update